View Older Stories View More Recent Stories
-
Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
Kiora Pharmaceuticals publishes phase 1 retinitis pigmentosa study data
-
Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway
-
Kiora Pharmaceuticals closes $24 million private placement
-
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors
-
Kiora Pharmaceuticals chief development officer to depart April 17
-
Kiora Pharmaceuticals Announces Management Team Changes
-
Kiora Pharmaceuticals reports $10.8 million loss for 2025
-
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials
-
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference
-
Kiora Pharmaceuticals adds retinal disease expert to advisory board
-
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board
-
Kiora Pharmaceuticals receives US patent for KIO-100 formulations
-
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds
-
Kiora Pharmaceuticals (KPRX) Tops Q3 EPS by 1c
-
Kiora Pharmaceuticals posts net income in Q3 amid ongoing clinical trials
-
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases
-
Kiora Pharmaceuticals joins RARE-X Vision Consortium for rare eye diseases
-
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
-
Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
-
Kiora Pharmaceuticals reports Q2 2025 results with two phase 2 trials
-
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases
-
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
-
Kiora Pharmaceuticals receives patent for KIO-104 ocular treatment
-
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease
-
Kiora Pharmaceuticals (KPRX) and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
-
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia
-
Kiora Pharmaceuticals (KPRX) Misses Q1 EPS by 52c
-
Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027
-
Kiora Pharmaceuticals Presents In Vivo Preclinical Data at ARVO 2025 Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathy
-
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference
-
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027
-
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting
-
Kiora Pharmaceuticals (KPRX) Secures U.S. Composition-of-Matter Patent Expanding Protection of KIO-104
-
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
-
Kiora Pharmaceuticals (KPRX) Receives Approval to Initiate KLARITY
-
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema
-
H.C. Wainwright Reiterates Buy Rating on Kiora Pharmaceuticals (KPRX)
-
Kiora Pharmaceuticals (KPRX) Misses Q3 EPS by 81c
-
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies
-
Kiora Pharmaceuticals (KPRX) Receives Investigational New Drug Approval to Initiate ABACUS-2
-
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa
-
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Kiora Pharmaceuticals (KPRX) Misses Q2 EPS by 53c
-
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
-
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences
-
Kiora Pharmaceuticals (KPRX) Granted EU Orphan Medicinal Product Designation for KIO-301
-
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
-
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation
-
Kiora Pharmaceuticals (KPRX) Appoints Lisa Walters-Hoffert to its Board
